A phase II, open-label, intra-patient dose-escalation study of erlotinib in patients with advanced non-small cell lung cancer who have failed prior chemotherapy.

Trial Profile

A phase II, open-label, intra-patient dose-escalation study of erlotinib in patients with advanced non-small cell lung cancer who have failed prior chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2011 Actual end date changed from (1 Oct 2009) to (1 Mar 2006) as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top